This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
News FDA Updates Law and Advocacy Technology Trends Viewpoints All News Media In-Depth Insights Pharmacist View Script-Ed Expert Interviews Podcasts Conferences Conference Coverage Conference Listing Resources Disease Awareness White Board Video American Pharmacists Month Sponsored Resources CME/CE Partners Publications Drug Topics Journal Total Pharmacy Journal Submission of Articles Events Virtual Events Total Pharmacy Solutions Summit Business Business Strategies Patient Services Pharmacy Inv
American medical research is a unique source of national pride and reputation — some would say the United States’ most important export. Yet Secretary of Health and Human Services Robert F. Kennedy Jr. seems bent on destroying our greatest successes. As the latest strike, Kennedy is going after the publications that disseminate medical research.
Rick Gates, chief pharmacy officer at Walgreens and chairman of the National Association of Chain Drug Stores, discussed the current status of retail pharmacies and the way they are reimbursed.
WASHINGTON — The Department of Health and Human Services will renew funding to states for cancer prevention and tracking efforts, alleviating anxieties among local officials about the future of their work. Over 50 notices had gone out as of Monday, an HHS spokesperson said. The rest of the awards will be sent to states, tribes, and other contractors “no later than early next week,” press secretary Emily Hilliard told STAT in an email.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Of those who do not support vaccines, 79% said a major reason for their opposition is that it should be the parents’ choice about whether to vaccinate their child and 40% cite safety concerns.
AbbVie said Monday that it would pay up to $2.1 billion to acquire Capstan Therapeutics , a startup developing CAR-T therapies for autoimmune conditions, fibrosis, and cancer. AbbVie will pay up to $2.1 billion in cash when the deal closes, according to a press release. The companies did not give further details about the financial terms or a timeline for completing the acquisition.
Jon Easter, RPh, joined Drug Topics to discuss pharmacists’ roles within health care teams following his presentation at the American Diabetes Association’s 85th Scientific Sessions.
281
281
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Jon Easter, RPh, joined Drug Topics to discuss pharmacists’ roles within health care teams following his presentation at the American Diabetes Association’s 85th Scientific Sessions.
Reducing inflammation has become all the rage lately, with many medical experts pointing to anti-inflammatory diets and other lifestyle changes as ways people can reduce their risk of chronic disease as they age. But a new study suggests that inflammation’s effects on health are more complex than scientists previously understood. In a study published in Nature Aging on Monday, researchers found that people living in non-industrialized societies experience less age-related chronic in
Panelists discuss how pneumococcal vaccines differ between conjugated vaccines (PCV-15, PCV-20, PCV-21) and polysaccharide vaccines (PPSV-23) in terms of immune response mechanisms and serotype coverage, with current CDC recommendations now including all adults aged 50 and older for vaccination while maintaining risk-based recommendations for adults 19-49 years with underlying conditions such as immunocompromising diseases, chronic heart/lung/liver disease, diabetes, alcohol use disorder, and ci
Across 3 different manufacturing lots, V116 (21-valent pneumococcal conjugate vaccine) demonstrated consistent immunogenicity and efficacy against S pneumoniae, which causes pneumococcal diseases.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Biopharmaceutical companies are at the forefront of medical innovation. Every treatment the industry develops, and every therapy brought forward, is the result of many years of research, risk and investment. While some critics continue to question the necessity of intellectual property (IP) and patents in this process, the data tells a compelling story.
A new blood test could predict preeclampsia as early as the first trimester. In a new study, researchers successfully predicted the early-onset subtype of the prenatal condition up to five months before clinical diagnosis. The findings are being presented Monday during the annual meeting of the European Society of Human Reproduction and Embryology, in Paris.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Thyroid conditions are more common than many people realize. According to the American Thyroid Association, an estimated 20 million Americans are living with some form of thyroid disorder. This small, butterfly-shaped gland located at the front of the neck plays a major role in regulating the body’s metabolism and energy use, so when something’s off, it can affect nearly every aspect of health.
By Larry K. Houck — A memorable Florida Orange Growers’ television ad campaign in the late 1970s proclaimed that “Orange juice from Florida isn’t just for breakfast anymore.” The Federal Controlled Substances Act (“CSA”) and its regulations require Drug Enforcement Administration (“DEA”) registrants to submit certain reports related to narcotic drug transactions, thefts and significant losses, and suspicious orders.
Gayathri Namasivayam, PhD, discusses how large language models are being used to extract structured oncology data from unstructured electronic health records to improve clinical efficiency, support real-world evidence generation, and enhance oncology pharmacy workflows.
Two weeks after Supernus Pharmaceuticals unveiled the proposed acquisition of Sage Therapeutics, all 338 employees from the latter company are being laid off, according to a Massachusetts Worker Adjustment and Retraining Notification.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Panelists discuss how tardive dyskinesia in older adults often goes unrecognized due to symptom overlap with normal aging, underscoring the importance of early screening, timely intervention with evidence-based treatments like VMAT2 inhibitors, and a multidisciplinary approach to preserve function, independence, and mental well-being.
ASPEN, Colo. — When Jessica Owens was toiling away in graduate school, she didn’t know what a venture capitalist was, much less that she’d one day launch her own firm and raise its inaugural $45 million fund. Owens co-founded Initiate Ventures, a Bay Area VC firm, after a winding career that spans roles at the Centers for Disease Control and Prevention and a stint in a cancer biology Ph.D. program before she ditched the lab to explore the world of finance.
The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in adult and paediatric patients with known or suspected Still’s disease, including systemic juvenile idiopathic arthritis. Announced by biopharma company Sobi, the approval makes Gamifant the first-ever FDA-approved therapy for MAS.
The FDA approves emapalumab-lzsg as the first treatment for macrophage activation syndrome in Still disease, offering a new treatment approach for patients with the rare condition.
Christopher Danes, PhD, discusses how discrete choice experiment data reveal key differences in patient and caregiver treatment preferences for ALK-positive (ALK+) non–small cell lung cancer (NSCLC) and how pharmacists can use these insights to guide shared decision-making, optimize supportive care, and personalize adherence strategies.
The takedown includes charges against 29 individuals alleged to be participating in transnational criminal organizations, who law enforcement said submitted more than $12 billion in fraudulent claims.
Pulmonary hypertension significantly increases the risk of disease progression and cardiovascular events in patients with myelofibrosis, emphasizing a need for routine screening.
AI scribes are mounting in popularity and generating hundreds of millions from venture capital. Duke researchers are now proposing a standard way to evaluate the technologies.
Gianni Scappaticci, PharmD, BCOP, discusses key considerations in therapy selection, limitations of current treatments, and the evolving role of pharmacists in managing chronic graft-versus-host disease (cGVHD) through patient education, adherence support, and integration of emerging therapies.
Subscribe Advertise About us Follow Follow Follow Follow GO Magazine PharmaTimes Magazine Archive Web Exclusives News Competitions Appointments Business Insights Webinars Thought Leadership Jobs UCB reports success in phase 3 study of fenfluramine for CDD by John Pinching | 30th Jun 2025 | News Positive trial results offer hope for those with ultra-rare epileptic disorder UCB has announced that its phase 3 trial evaluating fenfluramine in CDKL5 deficiency disorder (CDD) achieved its primary and
A new report from federal actuaries estimates that national health spending will increase by 7.1% in 2025, with spending growth set to outpace growth in the U.S. gross domestic product.
In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from CGT’s highly specialized operational strategies, particularly in terms of supply chain resilience and adaptability.
A recent study reveals high RSV antibody levels in older adults, highlighting the importance of vaccination and natural infection for enhanced immunity.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
503 
Let's personalize your content